0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover869.48%IV-76.58%PremiumJan 17, 2025Expiry Date6.54Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9561Delta0.0067Gamma1.20Leverage Ratio-0.0516Theta0.0004Rho1.15Eff Leverage0.0015Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet